Block’s reset trade
Block (SQ) jumped ~20% after laying out plans to cut headcount by nearly 50%. Brutal headline, clean math. When visibility is messy, investors grab whatever makes the model simpler: lower opex, better margins, faster path to cash.
Fintech has been stuck in the middle—volumes improving, products broadening, but competition relentless and the “keep spending to keep up” tax always lurking. A cut this deep says the posture is shifting from “build at speed” to “run for efficiency.” If revenue holds while the cost base shrinks, the multiple can move quickly.
Positioning did some work, too. Retail chatter latched onto “discipline,” and once you get that kind of gap, momentum money tends to show up. The risk is obvious: execution. Shrink too hard and you can boost near-term profitability while quietly starving product velocity, support, and the longer-cycle bets.
Capital intensity
The tape drew a bright line: push out your catalyst calendar or show up asking for capital, and you’ll wear it. Show up with a funded plan and fewer moving parts, and you get paid.
Rocket Lab (RKLB) fell double digits after delaying Neutron’s debut to end-2026. In launch, schedule is valuation. A slip stretches burn, pushes out the “prove it” moment, and forces customers—and investors—to downgrade confidence. In this funding backdrop, time risk is capital risk.
Kratos Defense filed to raise $1B via a share sale. Maybe the proceeds make sense. The market still has to digest new supply, and that’s an overhang when the crowd is dividing the universe into “can self-fund” versus “needs the market.”
Sempra went the other direction: a $65B capex plan through 2030, guiding 11% CAGR rate base growth, and explicitly saying no equity raises. Utilities are a simple chain when management keeps it simple: capex → rate base → earnings. The funding plan tells you whether dilution is part of the deal, and putting “no equity” next to a big build is the kind of clarity that keeps the capital cycle investable—especially with power-demand narratives (data centers, grid buildout) still front and center.
Growth prints
A few consumer/healthcare-adjacent names caught bids on straightforward signals: visible acceleration or a long-range framework investors can plug into a model without fighting every quarterly print.
Celsius (CELH) rose double digits after saying sales more than doubled YoY following the Alani Nu acquisition. The market likes M&A when it shows up quickly in the top line. In beverages, distribution wins compound, and the tape treated this as proof the combo travels beyond a deck.
Vital Farms set a $2B revenue target for 2030, pointing to volume growth. Long-dated targets are easy to discount, but they still shape expectations for capacity, category runway, and operating leverage. Leading with volume (not just price/mix) helps the durability case.
Ligand forecasted 23% CAGR royalty growth through 2030. Royalty models trade on visibility. Handing investors a long-run growth frame reduces the need to obsess over every near-term wobble in risk appetite.
Structure Therapeutics reported Q4 results (no details provided). More event-driven than a clean sector signal.
Deal tape stayed noisy and procedural: Netflix (NFLX) withdrew its bid for a Warner Bros. Discovery studio; Paramount–Skydance was said to be nearing a $111B deal; WBD called Paramount’s bid superior and gave Netflix four days to respond. It’s auction mechanics and deadline games, with everyone trying to look disciplined while leaking through the press.
Credit markets, meanwhile, stayed open without drama:
- Ameren priced 2036 senior notes.
- A Sirius XM unit priced an upsized $1.25B bond.
One quiet structural theme kept surfacing: expanding retail access to private credit—more yield for more people, with the footnote that liquidity and marks start to matter again when conditions tighten.
The market bought clarity today: cut costs with conviction, fund your capex without dilution, and put numbers on the growth story.